Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · Lancet · 2026-10-26
RCTn = 498
Xu et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in ChinaOncology · N Engl J Med · 2026-09-12
RCTn = 451
Zhao et al. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based TherapyOncology · Lancet Oncol · 2026-09-11
Secondary analysisn = 446
Hassing et al. Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trialOncology · Lancet · 2026-09-06
RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialOncology · Lancet Oncol · 2026-09-01
Secondary analysisn = 257
Dziadziuszko et al. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trialOncology · Lancet Oncol · 2026-09-01
RCTn = 438
Le et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trialOncology · Ann Oncol · 2026-08-21
RCTn = 797
Wakelee et al. Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study